The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Malaria is one of the most frequently occurring infectious diseases worldwide, with almost 1
million deaths and an estimated 243 million clinical cases annually. Several candidate …

Controlled human malaria infection (CHMI) entails deliberate infection with malaria
parasites either by mosquito bite or by direct injection of sporozoites or parasitized …

BACKGROUND The biology of Plasmodium vivax is markedly different from that of P.
falciparum; how this shapes the immune response to infection remains unclear. To address …

Plasmodium vivax is the most widespread human malaria parasite, in part because it can
form latent liver stages known as hypnozoites after transmission by female anopheline …

Plasmodium vivax continues to cause significant morbidity outside Africa with more than
50% of malaria cases in many parts of South and South-east Asia, Pacific islands, Central …

Abstract “The Primate Malarias” book has been a uniquely important resource for multiple
generations of scientists, since its debut in 1971, and remains pertinent to the present day …

Background. Major impediments to development of vaccines and drugs for Plasmodium
vivax malaria are the inability to culture this species and the extreme difficulty in undertaking …

Controlled human malaria infection (CHMI) provides a highly informative means to
investigate host-pathogen interactions and enable in vivo proof-of-concept efficacy testing of …

Introduction Plasmodium vivax causes significant public health problems in endemic
regions. A vaccine to prevent disease is critical, considering the rapid spread of drug …